Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient

Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient

Acute myeloid leukemia (AML) with inversion of chromosome 3 is characterized by overexpression of EVI1 and carries a dismal prognosis. Arsenic-containing compounds have been described to be efficacious in malignancies overexpressing EVI1. Here, we describe a case of AML with inv(3)(q21q26.2) treated...

Full description

Bibliographic Details
Main Authors: Nielsen, Torsten H., Johnson, Nathalie, Garnier, Nicolas, Kwan, Stanley, Yao, Lu, Cocolakis, Eftihia, Hébert, Josée, Morgan, Robert A., Paquet, Éric, Callahan, Kevin P., Jordan, Craig T., Assouline, Sarit, Miller, Wilson H., Mann, Koren K.
Format: Online
Language:English
Published: Frontiers Media S.A. 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570070/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570070/

Similar Items